NCT02809534View on ClinicalTrials.gov

A Study of Anlotinib in Patients With Hepatocellular Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Anlotinib

Anlotinib p.o. qd

Trial Locations (1)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY